BeOne Medicines (ONC) PT Raised to $445 at JPMorgan

October 1, 2026 9:06 AM

JPMorgan analyst Jessica Fye raised the price target on BeOne Medicines (NASDAQ: ONC) to $445.00 (from $425.00) while maintaining a Overweight rating.

No results found